On-Chip Peptide Mass Spectrometry Imaging for Protein Kinase Inhibitor Screening
- 16 December 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 89 (1) , 799-806
Abstract
Protein kinases are enzymes that are important targets for drug discovery because of their involvement in regulating the essential cellular processes. For this reason, the changes in protein kinase activity induced by each drug candidate (the inhibitor in this case) need to be accurately determined. Here, an on-chip secondary ion mass spectrometry (SIMS) imaging technique of the peptides was developed for determining protein kinase activity and inhibitor screening without a matrix. In our method, cysteine-tethered peptides adsorbed onto a gold surface produced changes in the relative peak intensities of the phosphorylated and unphosphorylated substrate peptides, which were quantitatively dependent on protein kinase activity. Using mass spectrometry imaging of multiple compartments on the gold surface in the presence of a peptide substrate, we screened 13,727 inhibitors, of which seven were initially found to have inhibitor efficiencies that surpassed 50%. Of these, we were able to identify a new breakpoint cluster region-abelson (BCR-ABL)T315I kinase inhibitor, henceforth referred to as KR135861. KR135861 showed no cytotoxicity and was subsequently confirmed to be superior to imatinib, a commercial drug marketed as Gleevec. Moreover, KR135861 exhibited a greater inhibitory effect on the BCR-ABLT315I tyrosine kinase, with an IC50 value as low as 1.3 μM. In in vitro experiments, KR135861 reduced the viability of both Ba/F3 cells expressing wild-type BCR-ABL and BCR-ABLT315I, in contrast to imatinib’s inhibitory effects only on Ba/F3 cells expressing wild-type BCR-ABL. Due to the surface sensitivity and selectivity of SIMS imaging, it is anticipated that our approach will make it easier to validate the small modifications of a substrate in relation to enzyme activity as well as for drug discovery. This mass spectrometry imaging analysis enables efficient screening for protein kinase inhibitors, thus permitting high-throughput drug screening with high accuracy, sensitivity, and specificity.Keywords
Funding Information
- National Research Foundation of Korea (2012R1A6A1029029, H-GUARD_2013M3A6B2078962, NRF-2012-009541, NRF-2015M3A9D7029894)
- Korea Research Institute of Standards and Science (GP206-0022)
This publication has 37 references indexed in Scilit:
- High-Throughput Screening of Small Molecule Libraries using SAMDI Mass SpectrometryACS Combinatorial Science, 2011
- Laser Desorption/Ionization Mass Spectrometric Assay for Phospholipase Activity Based on Graphene Oxide/Carbon Nanotube Double-Layer FilmsJournal of the American Chemical Society, 2010
- Ion Desorption Efficiency and Internal Energy Transfer in Carbon-Based Surface-Assisted Laser Desorption/Ionization Mass Spectrometry: Desorption Mechanism(s) and the Design of SALDI SubstratesAnalytical Chemistry, 2009
- Multivariate analysis of ToF‐SIMS data for biological applicationsSurface and Interface Analysis, 2009
- Protein Kinase Assay on Peptide‐Conjugated Gold Nanoparticles by Using Secondary‐Ion Mass Spectrometric ImagingAngewandte Chemie International Edition, 2007
- New Mass Spectrometric Assay for Angiotensin-Converting Enzyme 2 ActivityHypertension, 2006
- MALDI Matrices for Biomolecular Analysis Based on Functionalized Carbon NanomaterialsAnalytical Chemistry, 2004
- A Mass Spectrometry Plate Reader: Monitoring Enzyme Activity and Inhibition with a Desorption/Ionization on Silicon (DIOS) PlatformChemBioChem, 2004
- Imatinib Mesylate — A New Oral Targeted TherapyNew England Journal of Medicine, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001